October 20, 2026
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Case Report Presentation Demonstrating Significant Efficacy of BCV

British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT) in Manchester

Tokyo, Japan, October 20, 2026 – SymBio Pharmaceuticals Limited ("SymBio" or the "Company") today announced the presentation of a case report at the UK Paediatric BSBMTCT Annual Meeting held yesterday (October 19) in Manchester, UK, demonstrating that intravenous brincidofovir (IV BCV) exhibited an extremely potent and rapid antiviral effect against an adenovirus (AdV) infection in an immunocompromised pediatric patient whose condition was refractory to established antiviral drugs. The presentation was made by Dr. Beki James of Leeds Children's Hospital.


Given the current lack of approved treatment options for AdV infection, the patient's favorable response highlights the clinical potential of IV BCV and strongly supports the ongoing Phase III trial.

The clinical data presented demonstrated the high efficacy of IV BCV where existing treatment options had failed, and an extremely severe prognosis was anticipated. AdV infection is a life-threatening condition, particularly to immunocompromised pediatric patients, and the drastic reduction in viral load observed in this case underscores the potential of this drug.

Key Data Presented

Title: Trial Updates; Chronic GVHD Studies, Brincidofovir, and Others

Graph: Adenovirus viral load peaked in excess of 40,000,000 IU/ml after August 12, and rapid viral clearance was observed following three doses of IV BCV administered from August 18.



[Contact]

Investor Relations

Tel: +81(0)3 5472 1125

Notes

Note 1: Brincidofovir and Adenovirus Infection Following Hematopoietic Stem Cell Transplantation

Viral infections following hematopoietic stem cell transplantation represent an area of high unmet medical need. Notably, there are no established preventive or therapeutic measures for highly contagious adenovirus infections. The majority of patients are paediatric patients, and the infection can be fatal, creating a desperate need for effective therapeutic drugs. IV BCV demonstrated remarkably high efficacy in a Phase II clinical trial conducted in the United States, successfully achieving proof of concept (POC) for its antiviral activity. Based on the results of that trial, the current Phase III clinical trial was designed and subsequently initiated globally with the collaboration of physicians at leading transplant centers. Currently, in the U.S. and Europe, 41 patients have been enrolled as of October 15, 2026, with a target of 69 patients by the end of 2026 and 180 patients by the end of 2027.

Note 2: UK Paediatric BSBMTCT: UK Paediatric British Society of Blood and Marrow Transplantation and Cellular Therapy

For more details: https://bsbmtct.org/

Note 3: IU/mL (International Units per milliliter): A standard unit of measurement established by the World Health Organization (WHO) to quantify viral load, ensuring consistency across different laboratories and testing methods.

About SymBio Pharmaceuticals: BCV Business Strategy Centered on Three Therapeutic Areas

Since obtaining the global license for brincidofovir ("BCV") in September 2019, SymBio Pharmaceuticals has conducted joint research with world-leading research institutions in three therapeutic areas—double-stranded DNA virus infections, solid tumors, and neurodegenerative diseases—with the aim of unlocking BCV's potential in each area. SymBio is concentrating its management resources on the development of BCV, primarily for adenovirus infection following hematopoietic stem cell transplantation, progressive multifocal leukoencephalopathy ("PML"), glioblastoma, head and neck cancer, and EBV-associated gastric cancer. Through global business development, SymBio aims to maximize the business value of BCV.